Catechin Containing Mask for the Prevention of Influenza Infection

The Effects of Tea Catechin Extracts Containing Mask on the Prevention of Influenza Infection

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00812448

Enrollment

180

Registered

2008-12-22

Start date

2008-12-31

Completion date

2009-11-30

Last updated

2009-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza Infection

Keywords

prophylaxis, influenza infection, catechins, prophylaxis of influenza infection

Brief summary

The purpose of this study is to evaluate the effects of catechin extracts containing mask on prevention of influenza infection.

Detailed description

Catechins are the major components of tea flavonoids and are reported to possess physiological activities such as antiviral effects. Recent in-vitro experimental studies have revealed that tea catechin extracts possess the effects on the prevention of influenza infection. However, a limited number of studies have been conducted on the clinical effects. Based on these backgrounds, we designed a prospective randomized controlled study to evaluate the effects of tea catechin extracts containing mask on the prevention of influenza infection.

Interventions

DIETARY_SUPPLEMENTtea catechin extracts

catechins are composed of tea catechin extracts available in grren tea supplements

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Possible to wearing mask for three months * Possible to fill out a questionnaire personally * Obtained written informed consent before participation

Exclusion criteria

* Possessing some infectious diseases in need of therapy * Possessing tea or catechin allergy * diagnosed as inadequate for other reasons to participate the study by principal investigator

Design outcomes

Primary

Measure	Time frame
the incidence rate of influenza infection during the study	assessed at each month

Secondary

Measure	Time frame
the incidence rates of upper respiratory tract infections	assessed at each month
the severity of the symptoms and the duration of the cold among incident cases	assessed at each month
he incidence-free time for influenza or upper respiratory tract infections after the intervention	assessed at each month

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026